Prevalence and Severity of New coronavirus Disease` Clinical Course among HIV-infected People in Comparison with General Population
https://doi.org/10.31631/2073-3046-2021-20-3-30-36
Abstract
Relevance. The question about HIV-infected people as a risk group of morbidity and severe course of COVID-19 is still open.
Aim of our scientific work is to determine the prevalence and severity of COVID-19` clinical course in HIV-infected people in comparison with the general population.
Materials and methods. The information resources of COVID-19 registration in HIV-infected and HIV-negative people in Perm Region were studied for 2020.
Results. The prevalence of COVID-19 among HIV-infected people is lower than among HIV-negative people. There were no significant differences in the severity of COVID-19 clinical course in HIV-infected and HIV-negative people. There was no statistically significant dependence of the severity of COVID-19 clinical course in HIV-infected patients on the number of CD4 + T cells and the degree of viral load.
Conclusion. HIV-infected people are not a risk group of morbidity and severe course of COVID-19.
About the Authors
V. I. Sergevnin
Perm State Medical University named after аcademician E. A. Wagner
Russian Federation
Russian Federation
Viktor I. Sergevnin – Dr. Sci. (Med.), professor of the department of Epidemiology and Hygiene
26, Petropavlovskaya str., Perm, 614990
E. V. Sarmometov
Perm Regional Center for Prevention and Control of AIDS and Infectious Diseases
Russian Federation
Russian Federation
Evgeny V. Sarmometov – Cand. Sci. (Med.), Chief Physician
21, Sviyazeva st., Perm, 614088
M. V. Rozhkova
Perm Regional Center for Prevention and Control of AIDS and Infectious Diseases
Russian Federation
Russian Federation
Marina V. Rozhkova – epidemiologist, State Healthcare Institution
21, Sviyazeva st., Perm, 614088
References
1. Ladnaya N. N., Kozyrina N. V., Babikhina K. A. et al. Results of the study «Study of the prevalence of coronavirus infection COVID-19 among HIV-infected patients in Russia and the impact of the epidemic of coronavirus infection COVID-19 on the provision of medical care for HIV infection.» M. 2020. (In Russ.).
2. Mirzaei H, McFarland W, Karamouzian M, Hamid Sharifi H. COVID-19 Among People Living with HIV: A Systematic Review. // AIDS Behav. 2020; 1–8. doi: 10.1007/s10461-020-02983-2.
3. Ssentongo P, Heilbrunn ES, Ssentongo AE, et al. Prevalence of HIV in patients hospitalized for COVID-19 and associated mortality outcomes: a systematic review and metaanalysis. Presented at: IDWeek 2020; October 21-25, 2020. Poster 393. doi: 10.1101/2020.07.03.20143628.
4. Hsi-en Ho, Michael J Peluso, Colton Margus, et al. Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus. The Journal of Infectious Diseases, jiaa380. Published: 30 June 2020. doi: 10.1093/infdis/jiaa380.
5. Inciartea A, Gonzalez-Cordona A, Rojasa J, et al. Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study. // AIDS 2020;34(12):1775–1780. doi: 10.1097/QAD.0000000000002643.
6. Vizcarra P, Pérez-Elías M, Quereda C, et al. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort. // Lancet HIV. 2020;7(8):554–564. doi: 10.1016/S2352-3018(20)30164
7. Härter G, Spinner C, Roider J, et al. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. // Infection. 2020;48(5):681–686. doi: 10.1007/s15010-020-01438-z.
8. AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. // Life Sci. 2020; Jul 15;253:117592. doi: 10.1016/j.lfs.2020.117592.
9. NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19. Available at: NIAIDNews@ niaid.nih.gov (Last accessed April 29, 2020).
10. Wang Z, Chen X, Lu Y, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. // Biosci Trends. 2020;14:64–68. doi: 10.5582/bst.2020.01030.
11. Park SY, Lee JS, Son JS, et al. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. // J Hosp Infect. 2019;101:42–46. doi: 10.1016/j.jhin.2018.09.005.
12. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. // N Eng J Med 2020; 382:1787–1799. doi:10.1056/HEJMoa2001282.
Review
For citations:
Sergevnin V.I., Sarmometov E.V., Rozhkova M.V. Prevalence and Severity of New coronavirus Disease` Clinical Course among HIV-infected People in Comparison with General Population. Epidemiology and Vaccinal Prevention. 2021;20(3):30-36. (In Russ.) https://doi.org/10.31631/2073-3046-2021-20-3-30-36
Views:
659
Email this article 